2026-01-29 – Press Releases – www.prnewswire.com
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine leveraging SKYCovione’s recombinant protein-based platform and nanoparticle technology SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine…
